Hodgkin's and Non-Hodgkin's Lymphoma

Title: S0816, "A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma using Early Interim FDG-PET Imaging"

Purpose: To find out if it is possible to use early periodic PET scans to identify those patients who are not responding to a combination of standard chemotherapy called "ABVD" (the drugs doxorubicin, bleomycin, vinblastine and dacarbazine).

Eligibility: Subject will begin treatment with a combination of chemotherapy drugs called "ABVD." The drug combination includes: doxorubicin, bleomycin, vinblastine and dacarbazine. These drugs will be given to the subject through a needle in their vein over about one hour on Days 1 and 15 of a 28 day cycle. The subject will initially be given 2 cycles of this drug combination.

After completing two cycles of ABVD chemotherapy, the disease will be studied to find out the size of the tumor and its exact location in the body using a full body PET/CT scan.

The PET/CT scan will be sent to a centralized laboratory at Ohio State University ("the CALGB Imaging Core Laboratory") where a panel of three PET experts will review the PET/CT scans. If the three PET experts at the centralized laboratory decide that the PET/CT scan shows that your disease is inactive, then the subject will receive an additional 4 cycles of ABVD. If the PET experts determine that the PET scan shows that the disease is still active, then the subject will receive 6 cycles of BEACOPP chemotherapy as described below. If there is disagreement in the interpretation of the PET/CT scans between the local radiologist and the centralized laboratory, it will be the opinion of the three PET experts at the centralized laboratory that will determine which chemotherapy is recommended.

"BEACOPP" is a combination of seven drugs:
• Cyclophosphamide – given as an infusion in the veins on Day 1.
• Doxorubicin – given as an infusion in the veins on Day 1.
• Etoposide – given as an infusion in the veins on Days 1, 2 and 3.
• Procarbazine – given as pills to be taken by mouth on Days 1 through 7.
  • Prednisone – given as pills to be taken by mouth on Days 1 through 14
• Bleomycin – given as a short intravenous injection on Day 8.
• Vincristine – given as a short intravenous infusion on Day 8.
• The BEACOPP therapy will be given on a 21-day cycle. If the subject is given BEACOPP therapy they will receive 6 cycles of this treatment.

Principal Investigator: Martinez, Roberto

Phase: II

For more information, contact: Hagy, Melissa

Telephone Number: 410-601-9083

Email mhagy@lifebridgehealth.org

Approved Enrollment Number: 15

Current Enrollment: 0
Hodgkins' and Non-Hodgkins' Lymphoma

**Title:** COG AHOD0831 A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma

**Purpose:** Treatment of patients with high risk hodgkin disease.

**Eligibility:** Patients between aged 0 - 21 years of age with high risk hodgkin disease.

**Principal Investigator:** Wiley, Joseph M.

**Phase:** III

**For more information, contact:** Entrup, Stephanie

**Telephone Number:** 410-601-8393

**Email** sentrup@lifebridgehealth.org

**Approved Enrollment Number:** 10

**Current Enrollment:** 0